(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/207846 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
A61P 43/00 (2006.01)

(21) International Application Number:
PCT/EP2022/058669

(22) International Filing Date:
31 March 2022 (31.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2104556.2	31 March 2021 (31.03.2021)	GB
2107331.7	21 May 2021 (21.05.2021)	GB
2108170.8	08 June 2021 (08.06.2021)	GB

(71) Applicants: **CAMBRIDGE ENTERPRISE LIMITED** [GB/—]; The Old School Trinity Lane Cambridge, CAMBRIDGESHIRE CB2 1TN (GB). **KYMAB LIMITED** [GB/GB]; The Bennet Building (B930) Babraham Research Campus, CAMBRIDGE CB22 3AT (GB).

(72) Inventors: **O'RAHILLY, Stephen**; Cambridge Enterprise Limited The Old Schools Trinity Lane, CAMBRIDGE CB2 1TN (GB). **COLL, Anthony Patrick**; Cambridge Enterprise Limited The Old Schools Trinity Lane, CAMBRIDGE CB2 1TN (GB). **CIMINO, Irene**; Cambridge Enterprise Limited The Old Schools Trinity Lane, CAMBRIDGE CB2 1TN (GB). **LEE, E-Chiang**; The Bennet Building (B930) Babraham Research Campus, CAMBRIDGE CB22 3AT (GB). **LIU, Hui**; The Bennet Building (B930) Babraham Research Campus, CAMBRIDGE CB22 3AT (GB). **CARPENTER, Adam**; The Bennet Building (B930) Babraham Research Campus, CAMBRIDGE CB22 3AT (GB).

(74) Agent: **DOMENEGO, Bertrand** et al.; LAVOIX, 2, place d'Estienne d'Orves, 75441 PARIS CEDEX 09 (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: THERAPEUTIC INHIBITORS OF GDF15 SIGNALLING

(57) Abstract: This invention relates to antibodies that bind to and inhibit the activity of glial cell-derived neurotrophic factor family receptor alpha like (GFRAL) protein. The invention also relates to the GDF15-GFRAL signalling pathway as a therapeutic target for states of cachexia and conditions involving reduction in food intake and reduction in muscle and fat mass.

WO 2022/207846 A1